ATX Financial Planning LLC Purchases New Holdings in Abbott ...
📈 J. Stern & Co. LLP dramatically increased its stake by 12,439.6% to own 39,319,009 shares valued at $4.9 billion.
🏦 Major institutional investors including Norges Bank, Invesco, and Vanguard all added new or increased positions in Q4.
💰 Abbott reported Q1 revenue of $11.16 billion, beating estimates by $170 million with 7.8% year-over-year growth.
📊 The company beat EPS expectations with a result of $1.15 versus the consensus estimate of $1.14.
🚀 Management raised FY 2026 guidance to an EPS range of $5.38-$5.58, exceeding analyst group expectations.
💵 A quarterly dividend of $0.63 per share was declared with an ex-dividend date of July 15th.
👔 Corporate insiders including the CFO and a Director purchased shares in April at prices near $92.
Bullish Signals
- J. Stern & Co. LLP executed a massive buy, increasing its position by over 39 million shares, signaling strong institutional confidence.
- Abbott beat both revenue and EPS estimates, demonstrating operational strength and market demand for its products.
- The company raised its full-year earnings guidance above the consensus analyst expectation of $5.48.
- Revenue grew 7.8% year-over-year to $11.16 billion, indicating successful expansion in diagnostics, devices, or nutritionals.
- Strong balance sheet metrics include a quick ratio of 1.01 and a low debt-to-equity ratio of 0.56.
- A consistent dividend policy is supported by a healthy payout ratio of 70.59% and an attractive 2.8% yield.
Full Analysis
Abbott Laboratories (NYSE:ABT) saw significant institutional activity in the fourth quarter, highlighted by a massive position increase from J. Stern & Co. LLP, which added over 39 million shares to its stake, bringing total ownership to nearly $4.9 billion. Other notable investors including Norges Bank, Invesco Ltd., Ninety One UK Ltd., and Vanguard Group Inc. also increased or established new positions in the healthcare giant during this period.
Financially, Abbott reported strong quarterly results with revenue of $11.16 billion, beating analyst estimates by $170 million. The company posted earnings per share (EPS) of $1.15, surpassing the consensus of $1.14, and achieved a 7.8% year-over-year revenue growth. Management has provided forward guidance for FY 2026 EPS between $5.38 and $5.58, with analysts expecting a group average of $5.48.
The company maintains a robust balance sheet with a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott recently announced a quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record on July 15th, representing an annualized yield of 2.8%. Corporate insiders, including Director Daniel J. Starks and CFO Philip P. Boudreau, also made recent purchases in the stock.
